Company: ARWR
Filing Date: 2025-02-07
Form Type: 8-K
Source: 0001628280-25-004313
Chunk: 1

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-07
Form: 8-K
Item: Item 5.02
Chunk 1
---
 of restricted stock units valued at $771,200. These restricted stock units are scheduled to vest over three years.

There are no family relationships between Mr. Ingram and any of the Company’s directors or executive officers and, except as described below, Mr. Ingram does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

As noted above, Mr. Ingram currently serves as the President and Chief Executive Officer of Sarepta, and is also a member of its board of directors. As previously reported in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 (the “2024 Form 10-K”), the Company entered into an Exclusive License and Collaboration Agreement (the “ Collaboration Agreement”) with Sarepta for the co-development and commercialization of multiple clinical and preclinical programs on November 25, 2024. In connection with the Collaboration Agreement, the Company also entered into a Stock Purchase Agreement (the “ Stock Purchase Agreement” and, together with the Collaboration Agreement, the “ Agreements”) with an affiliate of Sarepta for a private placement of shares of common stock of the Company. For additional information on the Agreements, see “ Item 9B. Other Information,” under the heading “(a) License and Collaboration Agreement,” of Part II of the 2024 Form 10-K. As a result of the closing of the Agreements on February 7, 2025, Mr. Ingram is not considered an independent director under the Nasdaq Listing Rules.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                  
 ────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: February 7, 2025

  ARROWHEAD PHARMACEUTICALS, INC.                               
  By:                                  /s/ Kenneth Myszkowski   
                                       Kenneth Myszkowski       
                                       Chief Financial Officer